CRSP
Crispr Therapeutics AG
55.40$
+0.0%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | 10.0% | 10,277.6% | 11,020.5% | 2,650.0% | 11.9% | 6,648.4% | 5,577.7% | 7,277.1% | 6,870.8% | 3,446.4% | 437.8% | 1,634.4% | |
| – | 90.0% | -10,177.6% | -10,920.5% | -2,550.0% | 100.0% | -6,548.4% | -5,477.7% | -7,177.1% | -6,770.8% | -3,346.4% | -337.8% | -1,534.4% | |
| – | 47.6% | 14,154.6% | 14,568.7% | 12,850.5% | 234.7% | 8,379.7% | 7,320.0% | 6,625.6% | 9,012.2% | 4,703.3% | 638.0% | 2,018.3% | |
| – | 8.2% | 3,562.1% | 3,768.1% | 2,893.5% | 51.8% | 2,230.8% | 2,120.6% | 1,904.5% | 2,129.5% | 1,178.5% | 172.4% | 523.2% | |
| – | 55.2% | 17,716.7% | 18,336.8% | 15,744.0% | 284.5% | 10,610.4% | 9,440.6% | 7,677.7% | 11,141.7% | 5,586.9% | 789.8% | 2,437.1% | |
| – | 34.8% | -27,894.2% | -29,257.3% | -18,294.0% | -184.5% | -17,158.8% | -14,918.3% | -14,854.8% | -17,912.5% | -8,933.3% | -1,127.6% | -3,971.5% | |
| – | 8.9% | – | – | – | – | – | – | – | – | – | – | – | |
| – | 44.8% | -22,989.5% | -24,201.4% | -14,130.6% | -104.6% | -15,593.9% | -23,235.1% | -11,903.5% | -15,046.2% | -8,373.9% | -885.9% | -3,346.1% | |
| – | 0.1% | 143.7% | 248.9% | 145.5% | 2.0% | 128.2% | 144.8% | 69.6% | 71.1% | 57.5% | 9.4% | 22.6% | |
| – | 44.7% | -23,133.1% | -24,450.3% | -14,276.1% | -106.6% | -15,722.1% | -23,379.9% | -11,973.1% | -15,117.2% | -8,431.5% | -895.3% | -3,368.7% | |
| – | 47.2% | -22,030.6% | -23,264.2% | -13,343.4% | -90.8% | -15,046.4% | -22,719.4% | -11,404.8% | -14,391.0% | -8,077.7% | -1,085.3% | -3,390.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.